Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

Rhea-AI Summary

Nektar Therapeutics (NKTR) has announced its upcoming participation in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 27, 2025. The company will host a fireside chat at 2:00 p.m. Eastern Time (11:00 a.m. Pacific Time).

The presentation will be accessible through a webcast link and the Investor Events section of Nektar's website. Interested parties can access the replay for 30 days following the event. One-on-one meetings with management can be arranged through H.C. Wainwright representatives.

SAN FRANCISCO, March 20, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that the company will be webcasting its participation in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference:

• H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 27, 2025 at 2:00 p.m. Eastern Time / 11:00 a.m. Pacific Time – webcast link here

The fireside chat will be accessible via the webcast link above as well as on the Investor Events section of the Nektar website: https://ir.nektar.com/events-and-presentations/events. A replay of the presentation will be available for 30 days.

If you would like to request a one-on-one meeting with company management during the conference, please reach out to your respective H.C. Wainwright representative.

About Nektar Therapeutics

Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis and one in alopecia areata. Nektar's pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials. Nektar is headquartered in San Francisco, California. For further information, visit www.nektar.com and follow Nektar on LinkedIn.

Contact:

For Investors:

Corey Davis, Ph.D.
LifeSci Advisors, LLC
cdavis@lifesciadvisors.com  
212-915-2577

Ahu Demir, Ph.D.
LifeSci Advisors, LLC
ademir@lifesciadvisors.com
212-915-3820

For Media:

Madelin Hawtin
LifeSci Communications
603-714-2638
mhawtin@lifescicomms.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/nektar-therapeutics-to-participate-in-the-hc-wainwright-3rd-annual-autoimmune--inflammatory-disease-virtual-conference-302407356.html

SOURCE Nektar Therapeutics

FAQ

When is Nektar Therapeutics (NKTR) presenting at the H.C. Wainwright Conference 2025?

Nektar Therapeutics will present on Thursday, March 27, 2025, at 2:00 p.m. Eastern Time / 11:00 a.m. Pacific Time.

How long will the NKTR conference presentation replay be available?

The presentation replay will be available for 30 days following the event.

Where can investors access Nektar's (NKTR) H.C. Wainwright conference presentation?

The presentation can be accessed via the webcast link and the Investor Events section of Nektar's website at ir.nektar.com/events-and-presentations/events.

How can investors arrange one-on-one meetings with NKTR management during the conference?

Investors should contact their H.C. Wainwright representative to request one-on-one meetings with company management.